Telomir Pharmaceuticals (TELO) Short term Debt (2023 - 2026)
Telomir Pharmaceuticals (TELO) posted Short term Debt of $101000.0 for Q4 2023.
Telomir Pharmaceuticals (TELO) Short term Debt (2023 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Short term Debt for 1 years, with the latest figure at $101000.0 in Q4 2023.
- Quarterly Short term Debt changed N/A year-over-year to $101000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $101000.0 (changed N/A YoY) and the FY2023 annual result came in at $101000.0, changed N/A from the prior year.
- Short term Debt steadied at $101000.0 in Q4 2023 per TELO's latest filing.
- Over five years, Short term Debt peaked at $101000.0 in Q4 2023 and troughed at $101000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136,372.00 |
| Dec 31, 2023 | 101,000.00 |